This convenient service screens your compounds against over 50 targets known to be involved in human toxicity to aid with compound selection and early safety assessments. Available assay formats include enzymatic, biochemical binding, and radioligand binding assays.
The cardiac safety assessment assays are available for preclinical evaluation of the safety of compounds to identify toxic drugs potentially inducing fatal cardiac tachyarrhythmia.
Pharmacokinetics (PK) is a fundamental aspect of drug discovery for characterization of drug candidates in hit-to-lead and lead optimization programs in regards of adsorption, distribution, metabolism and excretion after administration to mice.
The identification of the Maximum-Tolerated Dose (MTD) is one of the first steps when taking a drug candidate from in vitro to in vivo phase of drug discovery. The MTD is the dose at which certain toxicity specified in advance occurs only in a predetermined tolerable proportion of the animals.
